Sun Pharma Advanced Research Company (SPARC) is cutting costs and optimizing R&D amid a portfolio pivot to high-value oncology and immunology assets, targeting $10 million in annual savings while ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果